Spetses 2025 Summer School on Functional Genomics of Metabolic Diseases
FEBS organized the Spetses Course where early career scientists explored functional genomics and its impact on major metabolic diseases
INTERCEPT-T2D Clinical Trial Launches in the EU centers
This Phase 2 randomized study is designed to evaluate dapansutrile’s efficacy and safety in approximately 300 patients with elevated blood glucose, systemic inflammation and at risk for complications of diabetes, despite use of standard-of-care anti-diabetic therapy
INTERCEPT-T2D featured in Research & Development Magazine
An article about INTERCEPT-T2D has been published in Research & Development Magazine on 28 March 2025.
Upcoming EASD 2025 – Vienna
INTERCEPT-T2D partners head to EASD 2025 in Vienna, where Yanni Morgenroth will give an oral presentation. More to come.
3rd Consortium Meeting – Stockholm, 25–26 February 2025
The consortium gathered in Stockholm on 25–26 February 2025 to reflect on 2024’s achievements and exchange insights from the past year
INTERCEPT-T2D at the 60th EASD Congress in Madrid
INTERCEPT-T2D members convened at the 60th Annual EASD Congress in Madrid to engage with experts on inflammation and type 2 diabetes and strengthen their collaboration.
Consortium members present at the 2024 Congress of the Société Francophone du Diabète
On March 20, 2024, at the Annual Congress of the Société Francophone du Diabète, two presentations highlighted the progress of the INTERCEPT-T2D project (CHUL and AP-HP)
INTERCEPT-T2D presented at the Bernoulli Lab 2024 Annual Meeting
The INTERCEPT-T2D project was presented during the 2024 annual meeting of the Bernoulli Lab, a key event bringing together the digital health research community from AP‑HP and Inria.
First patient enrolled in the project’s clinical study
First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor, Dapansutrile
Presentation of INTERCEPT-T2D’s Coordinator in the FFD newsletter (in french)
*Article in French* Read an article made by our partner “the Federation Française des diabétiques” about the project’s coordinator Nicolas Venteclef and the project INTERCEPT-T2D in their newsletter